Matrix Pharmaceutical

As of February 19, 2002, Matrix Pharmaceutical was acquired by Chiron, Corp. Matrix Pharmaceutical, Inc. manufactures novel drug product candidates for cancer based on its internal research and development capabilities and through in licensing of product candidates from research institutions or other pharmaceutical companies. The company also specializes in contract aseptic manufacturing for clinical and commercial supply. Matrix had developed an aqueous-based protein gel system for delivery of water-soluble chemotherapeutic agents and non-aqueous semi-solid systems for delivery of chemotherapeutic agents that are poorly water-soluble. Two product candidates that utilize the aqueous-based protein gel systems are being evaluated in human clinical trials. These include IntraDose Injectable Gel and MPI 5020 Radiopotentiator.